Cite
HARVARD Citation
Tomonari, T. et al. (2021). Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matched analysis. Hepatology research. 51 (4), pp. 472-481. [Online].